The biopharmaceutical company has closed an oversubscribed round co-led by Merck that also featured GlaxoSmithKline, Monsanto and Pfizer.
US-based biopharmaceutical company RaNa Therapeutics closed a $55m oversubscribed series B round yesterday co-led by MRL Ventures, the early-stage therapeutics fund of pharmaceutical company Merck, and hedge fund Baupost Group.
Pfizer Venture Investments, the corporate venturing arm of pharmaceutical company Pfizer; SR One, the corporate venturing subsidiary of pharmaceutical company GlaxoSmithKline; agricultural corporation Monsanto and MS Ventures, another Merck subsidiary, also contributed capital.
The round also included Partners Innovation Fund, which acts as the joint venture fund of Massachusetts General…
